Shares of Loxo Oncology Inc (NASDAQ:LOXO) have been given an average rating of “Buy” by the eighteen ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $188.73.

Several research analysts have recently weighed in on LOXO shares. BidaskClub downgraded Loxo Oncology from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 18th. Zacks Investment Research upgraded Loxo Oncology from a “hold” rating to a “buy” rating and set a $189.00 price target for the company in a research note on Saturday, August 4th. Cowen reiterated a “buy” rating on shares of Loxo Oncology in a research note on Thursday, August 9th. Stifel Nicolaus cut their price target on Loxo Oncology from $225.00 to $217.00 and set a “buy” rating for the company in a research note on Friday, August 10th. Finally, Cann reiterated a “buy” rating and set a $202.00 price target on shares of Loxo Oncology in a research note on Monday, August 27th.

In other Loxo Oncology news, CEO Joshua H. Bilenker sold 20,000 shares of the firm’s stock in a transaction dated Thursday, October 4th. The stock was sold at an average price of $164.94, for a total value of $3,298,800.00. Following the sale, the chief executive officer now owns 145,407 shares of the company’s stock, valued at approximately $23,983,430.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Jennifer Burstein sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $159.24, for a total value of $398,100.00. Following the completion of the sale, the vice president now directly owns 1,250 shares in the company, valued at approximately $199,050. The disclosure for this sale can be found here. Insiders have sold a total of 102,500 shares of company stock worth $16,798,550 in the last three months. 17.10% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. raised its holdings in shares of Loxo Oncology by 16.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,016 shares of the biopharmaceutical company’s stock valued at $22,382,000 after acquiring an additional 18,041 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Loxo Oncology by 15.5% in the 2nd quarter. BlackRock Inc. now owns 2,095,164 shares of the biopharmaceutical company’s stock valued at $363,468,000 after acquiring an additional 280,475 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Loxo Oncology in the 2nd quarter valued at about $454,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Loxo Oncology in the 2nd quarter valued at about $348,000. Finally, Stevens Capital Management LP purchased a new stake in shares of Loxo Oncology in the 2nd quarter valued at about $519,000. 97.77% of the stock is currently owned by hedge funds and other institutional investors.

Shares of LOXO stock traded down $7.06 on Monday, hitting $166.77. 281,936 shares of the stock were exchanged, compared to its average volume of 319,382. The company has a market capitalization of $5.37 billion, a price-to-earnings ratio of -31.41 and a beta of 2.26. Loxo Oncology has a one year low of $71.45 and a one year high of $208.95.

Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.24). The firm had revenue of $42.47 million during the quarter, compared to the consensus estimate of $38.55 million. During the same period last year, the firm earned ($2.45) EPS. On average, analysts predict that Loxo Oncology will post -2.52 EPS for the current fiscal year.

Loxo Oncology Company Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Featured Story: How Important is Technical Analysis of Stocks

Analyst Recommendations for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.